公开(公告)号：US09969736B2

公开(公告)日：2018-05-15

申请号：US15622838

申请日：2017-06-14

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun

IPC: C07D473/04 ,  C07D487/04 ,  C07D487/12 ,  C07D473/06

CPC classification number: C07D473/04 ,  C07D473/06 ,  C07D487/04 ,  C07D487/12

Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

公开(公告)号：US20170050966A1

公开(公告)日：2017-02-23

申请号：US15305892

申请日：2015-04-23

Applicant: HYDRA BIOSCIENCES, INC.

Inventor： Blaise S. Lippa ,  Xinyuan Wu ,  Qingyi Li ,  Iwona Wrona ,  Andrew J. Jackson ,  Bertrand L. Chenard ,  Christopher Matthew Liu ,  Guohua Liang ,  Matthew F. Baevsky ,  Richard Alan Earl ,  Lisa Mcqueen ,  Jared Smit ,  Brett A. Cowans

IPC: C07D473/08

CPC classification number: C07D473/08 ,  C07B2200/13

Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，药物制剂或其药物组合物及其用于治疗疼痛，炎性疾病，神经病，皮肤病，肺病和咳嗽的用途， 以及抑制瞬态受体电位A1离子通道（TRPA1）。

公开(公告)号：US09440973B2

公开(公告)日：2016-09-13

申请号：US14822232

申请日：2015-08-10

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun

IPC: A61K31/519 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K31/519

Abstract: This invention relates to novel Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.

公开(公告)号：US10329292B2

公开(公告)日：2019-06-25

申请号：US16031399

申请日：2018-07-10

Applicant: Boehringer Ingelheim International GmbH ,  Hydra Biosciences, Inc.

Inventor： Kai Gerlach ,  Christian Eickmeier ,  Achim Sauer ,  Stefan Just ,  Bertrand L. Chenard

IPC: C07D473/06 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K31/519 ,  A61K31/522 ,  C07D487/04

Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.

公开(公告)号：US10221177B2

公开(公告)日：2019-03-05

申请号：US15512213

申请日：2015-09-18

Applicant: HYDRA BIOSCIENCES, INC.

Inventor： Bertrand L. Chenard ,  Xinyuan Wu

IPC: C07D473/06 ,  A61K31/52 ,  C07D473/08 ,  A61K9/20 ,  C07K14/705 ,  A61K31/00

Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

公开(公告)号：US20180230149A1

公开(公告)日：2018-08-16

申请号：US15940253

申请日：2018-03-29

Applicant: Hydra Biosciences, Inc.

Inventor： Blaise S. Lippa ,  Xinyuan Wu ,  Qingyi Li ,  Iwona Wrona ,  Andrew J. Jackson ,  Bertrand L. Chenard ,  Christopher M. Liu ,  Guohua Liang ,  Matthew F. Baevsky ,  Richard A. Earl ,  Lisa Mcqueen ,  Jared Smit ,  Brett A. Cowans

IPC: C07D473/08

CPC classification number: C07D473/08 ,  C07B2200/13

Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

公开(公告)号：US09745272B2

公开(公告)日：2017-08-29

申请号：US14822079

申请日：2015-08-10

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun

IPC: C07D235/26 ,  C07D239/96

CPC classification number: C07D239/96 ,  C07D235/26

Abstract: This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.

公开(公告)号：US09447114B2

公开(公告)日：2016-09-20

申请号：US14822018

申请日：2015-08-10

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun

IPC: A61K31/519 ,  C07D495/04 ,  C07D491/048 ,  C07D491/04

CPC classification number: C07D495/04 ,  A61K31/519 ,  C07D491/04 ,  C07D491/048

Abstract: This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R1, R2, R3 and R4 have meanings given in the description.

公开(公告)号：US20160145257A1

公开(公告)日：2016-05-26

申请号：US15011523

申请日：2016-01-30

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun ,  Spencer David Kimball

IPC: C07D473/08

CPC classification number: C07D473/08 ,  C07D487/04 ,  C07D487/14

Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

公开(公告)号：US20160039772A1

公开(公告)日：2016-02-11

申请号：US14822079

申请日：2015-08-10

Applicant: Hydra Biosciences, Inc.

Inventor： Bertrand L. Chenard ,  Randall J. Gallaschun

IPC: C07D239/96

CPC classification number: C07D239/96 ,  C07D235/26

Abstract: This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.

Abstract translation: 本发明涉及式（I）的新型喹唑啉-2,4（1H，3H） - 二酮衍生物及其作为TRPC5调节剂的用途，含有它们的药物组合物及其用途用于治疗TRPC5的方法 受体介导的病症或病症。 R1，R2，R3和R4具有说明书中给出的含义。